ASEAN MedTech Insights cover art

ASEAN MedTech Insights

ASEAN MedTech Insights

Written by: Ran Chen
Listen for free

LIMITED TIME OFFER | Get 2 Months for ₹5/month

About this listen

 Welcome to ASEAN MedTech Insights, the premier podcast dedicated to the thriving medical technology landscape of Southeast Asia. Each episode, we explore the cutting-edge innovations, investment trends, and regulatory developments in one of the world's fastest-growing markets. Join us for exclusive interviews with the founders, executives, and visionaries shaping the future of healthcare in the ASEAN region.Copyright 2026 Ran Chen Biological Sciences Economics Science
Episodes
  • Pure Global: Singapore's AI MedTech Scene - Inside the HSA's New Fast-Track Sandbox

    Pure Global: Singapore's AI MedTech Scene - Inside the HSA's New Fast-Track Sandbox
    Mar 4 2026
    Singapore's Health Sciences Authority (HSA) has just launched a new fast-track regulatory sandbox for AI-powered medical devices. This pivotal move is set to accelerate the adoption of cutting-edge diagnostic and monitoring software, positioning Singapore as the premier gateway for digital health innovation in the ASEAN region. In this episode, we dissect what this new framework means for MedTech manufacturers. We explore the specific requirements companies must meet to qualify for the sandbox, the opportunities it unlocks for early market access, and the challenges related to data validation and post-market surveillance for adaptive AI algorithms. For years, AI MedTech developers faced a major hurdle: a regulatory system designed for hardware, not for software that learns and evolves. A groundbreaking AI diagnostic tool could spend years in regulatory limbo, unable to reach patients, while developers struggled to provide the right kind of evidence to authorities. This new sandbox directly addresses this pain point by creating a structured, yet accelerated, pathway for software as a medical device. Key questions answered in this episode: 1. What are the specific eligibility criteria for the HSA's new AI-SaMD sandbox? 2. How does this new pathway change the timeline for getting an AI medical device to market in Singapore? 3. What new types of evidence, especially for algorithm training and validation, are now required? 4. How can companies effectively manage post-market surveillance for an AI that is constantly learning? 5. Does this make Singapore the best market in ASEAN to launch a new digital health product? 6. What are the key cybersecurity and data privacy requirements that companies must meet? 7. How will the HSA handle version control and updates for approved AI algorithms? At Pure Global, we specialize in navigating complex regulatory landscapes. Our team combines local expertise with advanced AI tools to help MedTech innovators achieve market access in over 30 countries, including Singapore. From regulatory strategy and technical dossier submission to post-market surveillance, we offer end-to-end solutions. To streamline your entry into the ASEAN market, contact us at info@pureglobal.com or visit https://pureglobal.com/.
    Show More Show Less
    2 mins
  • Pure Global: Hanoi's New AI Regulation - Navigating the Data Trap.

    Pure Global: Hanoi's New AI Regulation - Navigating the Data Trap.
    Mar 3 2026
    This week, we dissect the sudden and impactful regulatory earthquake in Vietnam's MedTech sector. The Ministry of Health has released a new circular that reclassifies a huge swath of medical device software and AI tools into higher-risk categories, dramatically increasing the cost and time required for market approval. This isn't just about tougher standards. The new regulation also introduces a strict data localization mandate, forcing global companies to rethink their entire IT and data strategy for the Vietnamese market. We explore what this means on the ground and how manufacturers can navigate this challenging new landscape. A real-world example is a promising US-based scale-up with an AI-powered dermatology app that helps users screen for skin cancer. They were weeks away from launching in Vietnam under the old, simpler Class B pathway. Now, they are suddenly reclassified to Class C and face an unexpected, non-budgeted requirement to host all user data within Vietnam, forcing them to halt their launch and decide between a costly infrastructure investment or abandoning a key ASEAN market. Key Takeaways From This Episode: -What is Vietnam's new Circular 05/2026/TT-BYT and which device types are most affected? -How does reclassification from Class B to Class C impact your registration timeline and budget? -What are the specific technical and legal requirements of the new data localization rule? -Is this regulatory shift likely to spread to other ASEAN countries like Thailand or the Philippines? -How can you leverage your existing clinical data to meet the new, tougher evidence standards? -What are the hidden costs associated with setting up local data servers in Vietnam? -Should your company pause its entry into the Vietnamese market, or is there a strategic advantage to acting now? In a rapidly evolving market, staying ahead of regulatory changes is key to success. Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, using local expertise and advanced AI tools to streamline global market access. Whether you're navigating Vietnam's new circular, expanding into new markets, or managing post-market surveillance, we provide the strategic support you need. Contact us at info@pureglobal.com or visit https://pureglobal.com to learn how we can help.
    Show More Show Less
    2 mins
  • Pure Global: Kuala Lumpur's MedTech Export Surge & The Hidden Regulatory Maze

    Pure Global: Kuala Lumpur's MedTech Export Surge & The Hidden Regulatory Maze
    Mar 1 2026
    This week on ASEAN MedTech Insights, we delve into Malaysia's aggressive new strategy to dominate the global medical device market. Beyond its traditional role as a manufacturing powerhouse, Malaysia is making strategic moves to attract high-value MedTech investment, focusing on everything from R&D to complex device assembly. We explore the government's latest initiatives to streamline facility approvals and what this means for foreign companies. Learn how Malaysia is positioning itself as a prime hub for MedTech innovation and export, aiming to compete directly with established regional leaders. Consider this scenario. A European MedTech scale-up decides to move its manufacturing to Penang to lower costs and access the ASEAN market. They secure a facility quickly thanks to new government incentives. However, six months in, their first batch of smart diagnostic devices is barred from export to the EU because their Malaysian quality management system wasn't set up to meet MDR standards from day one, a classic dual-compliance failure. They face costly remediation and a major delay in revenue. Key Takeaways This Episode: 1. What specific incentives is Malaysia offering to foreign MedTech manufacturers right now? 2. How can companies navigate the dual compliance challenge of meeting both Malaysian MDA and international standards? 3. Which cities in Malaysia are becoming the next big MedTech hotspots and for which device categories? 4. What are the most common pitfalls in supply chain management when setting up a new facility in the region? 5. How is the Malaysian regulatory framework for Software as a Medical Device (SaMD) evolving? 6. What are the key differences between establishing a company in Malaysia versus Singapore for MedTech? 7. How can you leverage a Malaysian manufacturing base to accelerate access into other ASEAN markets? At Pure Global, we specialize in solving these complex challenges. We offer end-to-end regulatory consulting, from initial market strategy and local representation to compiling technical dossiers using advanced AI tools. Let us help you turn market access hurdles into a competitive advantage. Contact us at info@pureglobal.com or visit us at https://pureglobal.com/.
    Show More Show Less
    2 mins
No reviews yet